Standardization of objectives and response criteria for neoadjuvant immunotherapy in resectable squamous cell carcinoma of the head and neck.
International consensus on standardized immunotherapy response criteria for head and neck cancer will harmonize trials and speed guideline development.
International consensus establishes a standardized framework for neoadjuvant immunotherapy response criteria in resectable HNSCC, addressing a critical gap hindering trial harmonization. Adoption will enable cross-study comparisons and accelerate evidence-based guideline development.
What the study was
- Study design
- International expert consensus review
- Population
- Resectable squamous cell carcinoma of the head and neck (HNSCC) patients
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Cancer treatment reviews
Why it surfaced
International consensus on neoadjuvant immunotherapy endpoints in HNSCC; enables trial standardization; high-quality authorship.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.